(GLPG) Galapagos - Overview

Exchange: NASDAQ • Country: Belgium • Currency: USD • Type: Common Stock • ISIN: US36315X1019

Stock:

Total Rating 45

Risk 95

Buy Signal -0.20

Biotechnology +5.7
Biotechnology +5.6

Market Cap: 2,250m
Avg Trading Vol: 2.44M USD

ATR: 2.03%
Peers RS (IBD): 32.00

Risk 5d forecast
Volatility	28.1%
Relative Tail Risk	-9.80%

Reward TTM
Sharpe Ratio	0.81
Alpha	15.62

Character TTM
Beta	0.776
Beta Downside	0.696

Drawdowns 3y
Max DD	49.03%
CAGR/Max DD	-0.07

EPS (Earnings per Share)

EPS CAGR: 1.55%
EPS Trend: -27.2%

Last SUE: 0.10
Qual. Beats: 0

Revenue

Rev. CAGR: -20.34%
Rev. Trend: -12.4%

Last SUE: 0.02
Qual. Beats: 0

Description: GLPG Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -436.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA 1.42 > 1.0
NWC/Revenue: 1145 % < 20% (prev 1338 %; Δ -193.5% < -1%)
CFO/TA -0.07 > 3% & CFO -269.4m > Net Income -436.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.63 > 1.5 & < 3
Outstanding Shares: last quarter (65.9m) vs 12m ago -0.08% < -2%
Gross Margin: 50.44% > 18% (prev 0.57%; Δ 4987 % > 0.5%)
Asset Turnover: 6.91% > 50% (prev 5.75%; Δ 1.17% > 0%)
Interest Coverage Ratio: -10.69 > 6 (EBITDA TTM -503.2m / Interest Expense TTM 24.4m)

Altman Z'' 3.98

A: 0.80 (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b
B: -0.16 (Retained Earnings -678.8m / Total Assets 4.13b)
C: -0.06 (EBIT TTM -260.7m / Avg Total Assets 4.15b)
D: -0.27 (Book Value of Equity -340.8m / Total Liabilities 1.25b)
Altman-Z'' Score: 3.98 = AA

Beneish M -3.15

DSRI: 0.87 (Receivables 91.3m/87.2m, Revenue 286.9m/239.7m)
GMI: 1.13 (GM 50.44% / 56.80%)
AQI: 0.60 (AQ_t 0.07 / AQ_t-1 0.12)
SGI: 1.20 (Revenue 286.9m / 239.7m)
TATA: -0.04 (NI -436.0m - CFO -269.4m) / TA 4.13b)
Beneish M-Score: -3.15 (Cap -4..+1) = AA

What is the price of GLPG shares?

As of February 24, 2026, the stock is trading at USD 33.87 with a total of 73,246 shares traded.
Over the past week, the price has changed by -0.18%, over one month by -1.54%, over three months by +9.08% and over the past year by +27.52%.

Is GLPG a buy, sell or hold?

Galapagos has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell GLPG.

StrongBuy: 0
Buy: 0
Hold: 4
Sell: 1
StrongSell: 1

What are the forecasts/targets for the GLPG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	27.4	-19%
Analysts Target Price	27.4	-19%

GLPG Fundamental Data Overview February 24, 2026

Market Cap EUR = 1.91b (2.25b USD * 0.8484 USD.EUR)
P/E Forward = 344.8276
P/S = 7.8419
P/B = 0.7621
Revenue TTM = 286.9m EUR
EBIT TTM = -260.7m EUR
EBITDA TTM = -503.2m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.67b EUR (1.91b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -10.69 (Ebit TTM -260.7m / Interest Expense TTM 24.4m)
EV/FCF = 5.80x (Enterprise Value -1.67b / FCF TTM -287.0m)
FCF Yield = 17.23% (FCF TTM -287.0m / Enterprise Value -1.67b)
FCF Margin = -100.0% (FCF TTM -287.0m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = 50.44% ((Revenue TTM 286.9m - Cost of Revenue TTM 142.2m) / Revenue TTM)
Gross Margin QoQ = 84.76% (prev 92.79%)
Tobins Q-Ratio = -0.40 (set to none) (Enterprise Value -1.67b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 21.0% (US default 21%)
NOPAT = -206.0m (EBIT -260.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -66.9m / EBITDA -503.2m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.0m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.51% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -9.32% (EBIT -260.7m / Capital Employed (Equity 2.79b + L.T.Debt 7.50m))
RoIC = -7.67% (negative operating profit) (NOPAT -206.0m / Invested Capital 2.68b)
WACC = 8.74% (E(1.91b)/V(1.92b) * Re(8.78%) + (debt cost/tax rate unavailable))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
Fair Price DCF = unknown (Cash Flow -287.0m)
EPS Correlation: -27.22 | EPS CAGR: 1.55% | SUE: 0.10 | # QB: 0
Revenue Correlation: -12.41 | Revenue CAGR: -20.34% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.445 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.54 | Chg30d=-0.730 | Revisions Net=+1 | Growth EPS=+85.6% | Growth Revenue=-3.5%

Additional Sources for GLPG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle